We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMSALV
RNS Number : 5048K
SalvaRx Group plc
14 December 2018
14 December 2018
SalvaRx Group plc
("SalvaRx" or the "Company")
Nominated Adviser Status
SalvaRx announces that the Directors have been advised by its current nominated adviser ("Nomad"), Northland Capital Partners Limited ("Northland"), of its proposed merger with SP Angel Corporate Finance LLP ("SP Angel"). Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7.00 a.m. on 1 February 2019.
As a result, it is the intention of the Directors to transition the Company's Nomad role from Northland to SP Angel. This process has already started and at present the Directors anticipate a smooth and orderly transition of the Nomad role.
Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, in the unlikely event that the Company fails to appoint a replacement Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. In the event that the Company has failed to appoint a replacement Nomad by 4 March 2019, the admission of its AIM Securities will be cancelled.
Enquiries:
SalvaRx Group plc Ian Walters (Chief Executive) Tel: +1 203-441-5451 Northland Capital Partners Limited Tel: +44 (0) 20 Nominated Adviser and Broker 3861 6625 Matthew Johnson / Edward Hutton (Corporate Finance) Vadim Alexandre (Corporate Broking) Peterhouse Capital Limited Tel: +44 (0) 20 Joint Broker 7469 0932 Lucy Williams / Duncan Vasey
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCUSSBRWWAUARA
(END) Dow Jones Newswires
December 14, 2018 02:50 ET (07:50 GMT)
1 Year Salvarx Chart |
1 Month Salvarx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
